Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule - excipient ingredients: titanium dioxide; maize starch; silicon dioxide; gelatin; magnesium stearate - ursodeoxycholic acid is indicated in the treatment of chronic cholestatic liver diseases.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: magnesium stearate; colloidal anhydrous silica; maize starch; titanium dioxide; iron oxide yellow; gelatin - ursodox gh (ursodeoxycholic acid) capsule is indicated in the treatment of chronic cholestatic liver diseases.

Den europeiske union - engelsk - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic acid - xanthomatosis, cerebrotendinous; metabolism, inborn errors - bile and liver therapy - chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (ctx)) in infants, children and adolescents aged 1 month to 18 years and adults.

Israel - engelsk - Ministry of Health

mbi pharma ltd., israel - chenodeoxycholic acid - hard capsule - chenodeoxycholic acid 250 mg - chenodeoxycholic acid - the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (ctx)) in infants, children and adolescents aged 1 month to 18 years and adults.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic acid - xanthomatosis, cerebrotendinous; metabolism, inborn errors - terapija biljari u tal-fwied - aċidu chenodeoxycholic huwa indikat għall-kura ta ' l-iżbalji inborn ta ' l-aċidu bili primarja sintesi minħabba n-nuqqas hydroxylase sterol 27 (li jippreżentaw bħala cerebrotendinous xanthomatosis (ctx)) fl-trabi, tfal u adolexxenti ta ' età żmien xahar għal 18-il sena u adulti.

Den europeiske union - gresk - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic acid - xanthomatosis, cerebrotendinous; metabolism, inborn errors - Χολική και ηπατική θεραπεία - chenodeoxycholic οξύ ενδείκνυται για τη θεραπεία των ενδογενών πρωτογενούς χολικό οξύ σύνθεση λόγω ανεπάρκειας υδροξυλάση στερόλης 27 (παρουσιάζοντας ως cerebrotendinous xanthomatosis (ctx)) σε βρέφη, παιδιά και εφήβους ηλικίας 1 μηνός έως 18 ετών και ενήλικες.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; purified talc; polysorbate 80; hypromellose; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; macrogol 6000 - treatment of chronic cholestatic liver diseases

Den europeiske union - latvisk - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic skābes - xanthomatosis, cerebrotendinous; metabolism, inborn errors - Žults un aknu terapija - chenodeoxycholic acid norāda ārstēšanai iedzimts kļūdas primāro žults skābes sintēzes sakarā ar sterīnu 27 hidroksilāzes deficīts (uzrādot kā cerebrotendinous xanthomatosis (ctx)) zīdaiņiem, bērniem un pusaudžiem vecumā no 1 mēneša līdz 18 gadiem un pieaugušajiem.

Den europeiske union - estisk - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic happega - xanthomatosis, cerebrotendinous; metabolism, inborn errors - vere ja maksa ravi - chenodeoxycholic hape on näidustatud kaasasündinud vigadest esmane sapphapete sünteesi tõttu sterooli 27 hüdroksülaasi puudulikkus (esitades kui cerebrotendinous xanthomatosis (ctx)) imikutel, lastel ja noorukitel vanuses 1 kuu kuni 18 aastat ja täiskasvanute.

Den europeiske union - finsk - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic happo - xanthomatosis, cerebrotendinous; metabolism, inborn errors - bile- ja maksanhoito - chenodeoxycholic happo on tarkoitettu kohtelu synnyn ensisijainen sappihappoja synteesi johtuu sterolien 27 hydroksylaasin puutos (esitetään kuin cerebrotendinous xanthomatosis (jari)) pikkulapsilla, lapset ja nuoret vuotiaat 1 kuukausi – 18-vuotiaat ja aikuiset.